Press releases

Non Regulatory

December 10, 2021

Inceptua receives formal approval of the transfer of Oasmia’s marketing authorization for Apealea®

Regulatory

December 2, 2021

Nomination Committee appointed for the 2022 Annual General Meeting in Oasmia

Non Regulatory

November 26, 2021

Oasmia to present at Stora Aktiedagen Stockholm on December 2

Non Regulatory

November 26, 2021

Oasmia to present at the Erik Penser Bank Life Science Day on December 2

Regulatory

November 18, 2021

Interim report for the period January 1, 2021 – September 30, 2021

Non Regulatory

November 11, 2021

Invitation to presentation of Oasmia’s Q3 report on November 18

Regulatory

October 21, 2021

Oasmia announces global settlement of all disputes with MGC Capital, former Board Members of Oasmia and members of former management

Non Regulatory

October 20, 2021

Bulletin from Extraordinary General Meeting in Oasmia Pharmaceutical AB

Non Regulatory

September 24, 2021

Oasmia to present at Naventus Life Science Summit on September 29

Regulatory

September 20, 2021

Notice of Extraordinary General Meeting in Oasmia Pharmaceutical AB

Non Regulatory

September 17, 2021

Oasmia signs agreement with FarmaMondo to commercialize Paclical® in Russia & CIS

Non Regulatory

August 31, 2021

Oasmia to present at Aktiedagen Stockholm on September 7

Non Regulatory

August 26, 2021

Oasmia strengthens internal capabilities with the appointments of Head of Clinical Development & Head of Regulatory Affairs

Regulatory

August 19, 2021

Interim report for the period January 1, 2021 – June 30, 2021

Non Regulatory

August 10, 2021

Invitation to presentation of Oasmia’s Q2 report on August 19

Non Regulatory

June 30, 2021

Cantrixil positive Phase I trial data published in the journal Cancers

Non Regulatory

June 28, 2021

Oasmia transfers Nordic commercialization rights for Apealea® to Inceptua

Non Regulatory

June 10, 2021

First Patient enrolled in the SAKK Investigator-Initiated Phase 1b trial of Docetaxel Micellar in Advanced Prostate Cancer

Non Regulatory

June 9, 2021

Oasmia Provides a R&D Update on its Technology Platforms

Non Regulatory

June 2, 2021

Oasmia to present at Aktiespararna’s Småbolagsdagar on June 9

Regulatory

May 27, 2021

Report from Annual General Meeting in Oasmia Pharmaceutical AB

Regulatory

May 27, 2021

Interim report for the period January 1, 2021 – March 31, 2021

Regulatory

April 29, 2021

Oasmia publishes Annual Report for 2020

Regulatory

April 27, 2021

Notice of Annual General Meeting in Oasmia Pharmaceutical AB

Regulatory

April 27, 2021

The Nomination Committee of Oasmia proposes Andrea Buscaglia as new Board member

Non Regulatory

April 21, 2021

Phase 1b Trial of Oasmia’s Docetaxel Micellar in Advanced Prostate Cancer is Granted Ethical Committee Approval and can be Initiated

Non Regulatory

April 12, 2021

Oasmia Presents Cantrixil Final Phase I Data at the 2021 AACR Annual Meeting

Non Regulatory

April 1, 2021

Oasmia Pharmaceutical Appoints Dr Reinhard Koenig as Chief Scientific Officer

Non Regulatory

March 26, 2021

Oasmia to Present Cantrixil Final Phase I Data at the 2021 AACR Virtual Annual Meeting

Regulatory

March 24, 2021

Oasmia wins sole rights to record patents in its own name and is awarded full legal costs

Non Regulatory

March 24, 2021

European Patent Office Informs Oasmia of its Intention to Grant XMeNa Patent

Non Regulatory

March 3, 2021

Oasmia and Karolinska Institutet to collaborate on the biological potential of Oasmia’s proprietary drug delivery platform

Regulatory

March 1, 2021

Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program

Regulatory

February 19, 2021

Year-end report^[1] for the shortened^[2] financial year May 1, 2020 – December 31, 2020

Non Regulatory

February 16, 2021

Invitation to presentation of Oasmia’s Year-end report on February 19

Non Regulatory

January 29, 2021

Oasmia Pharmaceutical Appoints Dr. Heidi B. Ramstad as Chief Medical Officer